# Liposomal Bupivacaine With Standard Bupivacaine Versus Dexmedetomidine With Standard Bupivacaine

> **NCT06235606** · PHASE3 · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 96 (actual)

## Conditions studied

- Acute Pain

## Interventions

- **DRUG:** Bupivacaine Liposome 13.3 Milligrams/Milliliter [Exparel]
- **DRUG:** Dexmedetomidine 0.5milligram (50micrograms)

## Key facts

- **NCT ID:** NCT06235606
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-08
- **Primary completion:** 2025-11-03
- **Final completion:** 2026-02-05
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06235606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06235606, "Liposomal Bupivacaine With Standard Bupivacaine Versus Dexmedetomidine With Standard Bupivacaine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06235606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*